Abstract
In continuance of our search for new anticancer agents, we report herein the design, synthesis, and anticancer evaluation of oxadiazole analogues. Two series (4a-h and 4i-q) of new oxadiazole analogues were designed based on heterocyclic (1,3,4-oxadiazole)-linked aryl core of IMC-038525 (tubulin polymerization inhibitor), NSC 776715, and NSC 776715 and synthesized. All the compounds were fully characterized by infrared, nuclear magnetic resonance spectroscopy, and mass spectral data and the purity of compounds was checked by elemental analysis (C, H, and N analysis). Further seven compounds were evaluated for anticancer activity on nine different panels of 60 cell lines (60 NCI cancer cell lines) according to the National Cancer Institute screening protocol and percent growth and percent growth inhibition was calculated at 10 µM drug concentration. Ten compounds were evaluated for anticancer activity on two cancer cell lines (HeLa and MDA-MB-435) as per the standard protocol reported at four different drug concentrations (10−7, 10−6, 10−5, and 10−4 µM) and GI50, LC50, and TGI dose-related parameters were calculated. The compound 4j showed maximum anticancer activity at 10 µM, and was found to have higher sensitivity against MOLT-4, IGROV1, HCT-116, and K-562 with percent growth inhibitions of 50.38, 48.45, 46.26, and 46.26 respectively. The compound 4j showed superior anticancer activity than imatinib on 41 human cancer cell lines. The compound 4p showed anticancer activity with GI50 of 36.7 and 46.5 µM against HeLa and MDA-MB-435 cell lines, respectively.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdel-Aziz M, Metwally KA, Gamal-Eldeen AM, Aly OM (2016) 1,3,4-oxadiazole-2-thione derivatives; novel approach for anticancer and tubulin polymerization inhibitory activities. Anti-Cancer Agents Med Chem 16(9):269–277
Ahsan MJ, Sharma J, Monika S, Jadav SS, Yasmin S (2014) Synthesis and anticancer activity of N-aryl-5-substituted-1,3,4-oxadiazol-2-amine analogues. BioMed Res Inter 2014, Article ID: 814984. http://dx.doi.org/10.1155/2014/814984.
Aydemir N, Bilaloglu R (2003) Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. Mut Res 537:43–51
Azam F, El-gnidi BA, Alkskas IA (2010) Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides. Eur J Med Chem 45:2817–2826
Bakht MA, Yar MS, Abdel-Hamid SG, Al-Qasoumi SI, Samad A (2010) Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole analogues. Eur J Med Chem 45:5862–5869
Boyd MR, Paull KD (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91–109
Corona P, Carta A, Loriga M, Vitale G, Paglietti G (2009) Synthesis and in vitro antitumor activity of new quinoxaline derivatives. Eur J Med Chem 44:1579–1591
NCI/NIH (2014) Development therapeutic program NCI/NIH. http://dtp.nci.nih.gov. Accessed 13 November 2014
Finger GC, Dickerson DR, Starr LD, Orlopp DE (1965) Aromatic fluorine compounds. XIII. Substituted N-phenylglycine ethyl esters and hydrazides. J Med Chem 8:405–407. https://ncats.nih.gov/files/ZD4054.pdf. Accessed 18 September 2015
Karabanovich G, Zemanová J, Smutný T, Székely R, Šarkan M, Centárová I, Vocat A, Pávková I, Čonka P, Němeček J, Stolaříkov J, Vejsová M, Vávrová K, Klimešová V, Hrabálek A, Pávek P, Cole ST, Mikušová K, Roh J (2016) Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and thiadiazoles as selective antitubercular agents active against replicating and nonreplicating Mycobacterium tuberculosis. J Med Chem 59:2362–2380
Khan MU, Akhtar T, Al-Masoudi NA, Stoeckli-Evans H, Hameed S (2012) Synthesis, crystal structure and anti-HIV activity of 2-adamantyl/adamantylmethyl-5-aryl-1,3,4-oxadiazoles. Med Chem 8:1190–1197
Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screening using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757–766
Prabhakaran V, Balasubramanium R, Sathe P, Krishna CM, Juvekar A (2014) In vitro anticancer activity of monosubstituted chalcone derivatives. Int J Tumor The 3:1–9
Rajak H, Thakur BS, Singh A, Raghuvanshi K, Sah AK, Veerasamy R, Sharma PC, Pawar RS, Kharya MD (2013) Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity. Bioorg Med Chem Lett 23:864–868
Ramaprasad GC, Kalluraya B, Kumar BS, Mallaya S (2013) Synthesis of new oxadiazole derivatives as anti-inflammatory, analgesic, and antimicrobial agents. Med Chem Res 22:5381–5389
Sangshetti JN, Chabukswar AR, Shinde DB (2011) Microwave assisted one pot synthesis of some novel 2,5-disubstituted 1,3,4-oxadiazoles as antifungal agents. Bioorg Med Chem Lett 21:444–448
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823
Siegel RL, Miller DK, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
Takiar R, Nadiyal D, Nandakumar A (2010) Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Can Pre 11:1045–1049
Tuma MC, Malikzay A, Ouyang X, Surguladze D, Fleming J, Mitelman S, Camara M, Finnerty B, Doody J, Chekler EL, Kussie P, Tonra JR (2010) Antitumor activity of IMC-038525, a novel oral tubulin polymerization inhibitor. Transl Oncol 3:318–325
Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112–1116
WHO (2014) WHO World Cancer Report. http://www.nydailynews.com/life-style/health/14-million-people-cancer-2012-article-1.1545738. Accessed 12 December 2014
Zhang K, Wang P, Xuan L, Fu X, Jing F, Li S, Liu Y, Chen B (2014) Synthesis and antitumor activities of novel hybrid molecules containing 1,3,4-oxadiazole and 1,3,4-thiadiazole bearing Schiff base moiety. Bioorg Med Chem Lett 24:5154–5156
Acknowledgments
Antiproliferative data were provided by National Cancer Institute (NCI US), Bethesda, MD, USA and Anticancer Drug Screening Facility (ACTREC), Navi Mumbai, India. We are grateful for all help provided by Prof. Doug Smallwood and Mr. Mohammed Nayel NCI US), Bethesda, MD, USA. We are also grateful for all help provided by Dr. Jyoti Kode, ACTREC, Navi Mumbai, India. The people holding the management of Maharishi Arvind College of Pharmacy, Jaipur, Rajasthan, India is acknowledged for providing research facilities. We are also grateful to Dr. Reddy Institute of Life Science, Hyderabad, Andhra Pradesh, India for providing spectral data of synthesized compounds. The author VS is thankful to DST, Jaipur for partial financial support (1156/2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Mohit Agarwal and Vikram Singh contributed to this work equally.
Rights and permissions
About this article
Cite this article
Agarwal, M., Singh, V., Sharma, S.K. et al. Design and synthesis of new 2,5-disubstituted-1,3,4-oxadiazole analogues as anticancer agents. Med Chem Res 25, 2289–2303 (2016). https://doi.org/10.1007/s00044-016-1672-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-016-1672-1